What is the recommended management of tachycardia in patients with established heart disease?

Tachycardia Management in Patients with Heart Disease

For patients with established heart disease presenting with tachycardia, immediate hemodynamic assessment determines the pathway: unstable patients require immediate synchronized cardioversion, while stable patients proceed through a stepwise algorithm based on QRS width—narrow-complex tachycardias (SVT) are managed with vagal maneuvers followed by adenosine then rate-control agents, whereas wide-complex tachycardias (presumed ventricular tachycardia) require amiodarone or procainamide, with catheter ablation as definitive therapy for recurrent ventricular arrhythmias in structural heart disease. 1, 2

Immediate Hemodynamic Stratification

Unstable tachycardia (hypotension, altered mental status, shock, chest pain, acute heart failure) mandates immediate synchronized cardioversion starting at 50–100 J, escalating as needed—this is non-negotiable regardless of tachycardia type. 1 Never delay cardioversion to attempt pharmacologic conversion in unstable patients, as this directly impacts mortality. 1

Narrow-Complex Tachycardia (SVT) in Heart Disease Patients

Stable Narrow-Complex Tachycardia Algorithm

Step 1: Vagal Maneuvers

• Modified Valsalva maneuver (supine position, bearing down for 10–30 seconds generating 30–40 mm Hg intrathoracic pressure) converts approximately 43% of cases. 1
• Carotid sinus massage for 5–10 seconds after confirming absence of carotid bruit is an acceptable alternative. 1
• Diving reflex (ice-cold wet towel to face) provides another vagal option. 1
• Never apply pressure to eyeballs—this is contraindicated. 1

Step 2: Adenosine (Drug of Choice)

• Adenosine converts 90–95% of AVNRT/AVRT episodes and is the pharmacologic first-line after failed vagal maneuvers. 1
• Dosing protocol: 6 mg rapid IV push with 20 mL saline flush; if no conversion within 1–2 minutes, give 12 mg rapid IV push. 1
• Critical safety requirement: A defibrillator must be immediately available because adenosine can precipitate atrial fibrillation that may rapidly degenerate to ventricular fibrillation. 1
• Reduce initial dose to 3 mg in patients on dipyridamole, carbamazepine, or with transplanted hearts; increase dose with theophylline or caffeine use. 1
• Contraindicated in asthma patients. 1

Step 3: IV Calcium-Channel Blockers or Beta-Blockers

• In patients with heart disease, this step requires extreme caution: IV diltiazem or verapamil achieve 64–98% conversion but are contraindicated in systolic heart failure and must be avoided if ventricular tachycardia or pre-excited atrial fibrillation is possible. 1
• Infuse over up to 20 minutes to minimize hypotension risk. 1
• IV beta-blockers are safer alternatives in heart disease patients with an excellent safety profile, though slightly less effective than calcium-channel blockers. 1

Step 4: Synchronized Cardioversion

• When pharmacologic therapy fails or is contraindicated in stable patients, synchronized cardioversion (after adequate sedation) yields 80–98% success. 1

Critical Pitfall: Pre-Excited Atrial Fibrillation (Wolff-Parkinson-White)

If wide QRS complexes appear during "SVT" in a heart disease patient, suspect pre-excited atrial fibrillation—immediately withhold adenosine, diltiazem, verapamil, and digoxin as these can enhance accessory-pathway conduction and precipitate ventricular fibrillation. 1 Treat stable pre-excited AF with IV procainamide or ibutilide; unstable cases require immediate cardioversion. 1

Wide-Complex Tachycardia (Presumed Ventricular Tachycardia) in Structural Heart Disease

Acute Management of Stable VT

In patients with structural heart disease (prior MI, dilated cardiomyopathy, nonischemic cardiomyopathy), wide-complex tachycardia should be presumed ventricular tachycardia until proven otherwise—treat with IV amiodarone or procainamide, never with calcium-channel blockers. 2, 3 The risk of misdiagnosing VT as SVT with aberrancy and administering AV-nodal blockers can be fatal in this population. 1, 2

Long-Term Management of Recurrent VT in Structural Heart Disease

Catheter ablation is upgraded to preferred therapy for patients with ischemic cardiomyopathy and recurrent ventricular tachycardia, as it addresses the arrhythmogenic substrate rather than merely suppressing episodes. 4, 2 Single-procedure success rates approach 70–80% in experienced centers, though recurrence remains a challenge particularly in dilated cardiomyopathy. 5

Optimal treatment of the underlying heart disease is essential and takes precedence—ensure guideline-directed medical therapy for heart failure is maximized before escalating antiarrhythmic therapy. 4, 6

Implantable cardioverter-defibrillators (ICDs) prevent sudden cardiac death but do not prevent VT recurrence; patients with recurrent ICD shocks have high morbidity and mortality, necessitating additional suppressive therapy. 6, 3

Antiarrhythmic drugs (amiodarone, sotalol) can reduce VT episodes but have not been shown to decrease mortality in structural heart disease—use them as adjuncts to ICD therapy or when ablation is not feasible. 2, 3

Risk Stratification for Primary Prevention ICD

In dilated cardiomyopathy, primary prophylactic ICD decisions should incorporate cardiac MRI findings, genetic testing results, and clinical factors beyond left ventricular ejection fraction alone, as LVEF criteria remain controversial. 4 This represents an evolution from purely LVEF-based criteria used in ischemic cardiomyopathy.

Special Considerations in Complex Congenital Heart Disease

Following complex atrial surgeries (Mustard, Senning, Fontan procedures), narrow-complex tachycardias arise from postoperative scarring and altered conduction pathways—conventional ECG interpretation is limited, requiring three-dimensional electroanatomical mapping and detailed anatomical knowledge for accurate diagnosis. 7, 8 Catheter ablation achieves high acute success but remains prone to recurrences in this population. 7

Common Pitfalls in Heart Disease Patients

• Never use calcium-channel blockers or beta-blockers if any suspicion exists for pre-excited atrial fibrillation or ventricular tachycardia—this can precipitate hemodynamic collapse. 1
• Always have a defibrillator ready when administering adenosine, as it can trigger dangerous atrial fibrillation even in patients with underlying heart disease. 1
• Amiodarone and digoxin are no longer recommended for acute narrow-complex SVT management. 1
• Post-conversion premature ventricular complexes can re-initiate SVT—consider prophylactic antiarrhythmic therapy to prevent immediate recurrence. 1
• Monitor for bradyarrhythmias and hypotension after initiating chronic rate-control agents, particularly in patients with compromised ventricular function. 1